Hims & Hers Health (NYSE: HIMS) tumbled 5.6% through 12:20 p.m. ET Thursday after Bank of America analysts gave mixed ...

American doctors, who tracked over 37 million people, said the injections put users at higher risk of nonarteritic ischemic ...

CardCash.com to Offer Cost-Effective Solutions for High-Demand GLP-1 Medications as Prescription Drug Market Grows SCHAUMBURG, IL / ACCESS ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Ozempic may also help people drink less alcohol. Primary care doctors are concerned about patients accessing GLP-1s through ...

Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.

Several local companies are developing technologies that they hope could replace a painful poke with something that feels more like having Velcro against your skin for a few minutes.

Swiss drugmaker Roche began a study last year of its experimental drug, RG6237, as a monotherapy in people with high body ...

There are many opportunities available in the international markets that never make the news in the US. The VEA and VWO ETFs ...

When celebrities reveal their experiences with newer weight-loss drugs, there are upsides and downsides for patients and ...

Small studies link Ozempic and similar drugs to rare but serious eye conditions. However, experts say there's no need to ...

Six percent of Americans have used Ozempic, Wegovy and similar drugs. They’re unwitting experimental subjects.